Research Article
Period Family of Clock Genes as Novel Predictors of Survival in Human Cancer: A Systematic Review and Meta-Analysis
Table 1
Main characteristics of the studies included in the meta-analysis.
| | Study (publish year) | Country | Cancer type | Gene type | Sample size | Detection method | Follow-up (months) | Expression (+) (%) | Cut-off | Age | Stage | NOS scores |
| | Zhao (2014) [13] | China | GC | PER1 | 246 | IHC | 25 (1-161) | (103/143) 41.87% | | 57.1 (23–79) | I-IV | 8 | | Zhao (2014) [13] | China | GC | PER2 | 246 | IHC | 25 (1-161) | (86/160) 34.96% | | 57.1 (23–79) | I-IV | 8 | | Xiong (2017) [29] | China | OSCC | PER2 | 40 | IHC | >60 | (16/24) 40% | | N/A | I-IV | 8 | | Liu (2014) [16] | China | NSCLC | PER1 | 130 | IHC | >60 | (86/44) 66.15% | | 61 (38–79) | I-III | 8 | | Liu (2014) [16] | China | NSCLC | PER2 | 130 | IHC | >60 | (77/53) 59.23% | | 61 (38–79) | I-III | 8 | | Liu (2014) [16] | China | NSCLC | PER3 | 130 | IHC | >60 | (82/48) 63.08% | | 61 (38–79) | I-III | 8 | | Wang (2015) [30] | China | CC | PER1 | 203 | IHC | 61 (9-89) | (182/21) 89.66% | | 68 (22–95) | I-IV | 8 | | Wang (2012) [31] | China | CC | PER3 | 203 | IHC | 61 (9-89) | (167/36) 82.27% | | 65 (22–95) | I-IV | 8 | | Tavano (2015) [17] | Italy | PDA | PER2 | 34 | qRT-PCR | 25.2 | N/A | N/A | 68.5 (51–74) | IIA-III | 8 | | Oshima 2011 [37] | Japan | CRC | PER2 | 202 | qRT-PCR | >60 | (101/101) 50% | Median value | 66 | N/A | 8 | | Hwang-Verslues (2013) [32] | Taiwan | BC | PER2 | 101 | qRT-PCR | 0-120 | (50/51) 49.50% | N/A | | N/A | 6 | | Pluquet (2013) [33] | France | GBM | PER1 | 60 | qRT-PCR | >80 | (31/29) 51.67% | Average value | N/A | N/A | 7 | | Hu (2014) [34] | Taiwan | GC | PER1 | 29 | qRT-PCR | 60 | N/A | N/A | 69.76 (51–81) | I-IV | 7 | | Hu (2014) [34] | Taiwan | GC | PER2 | 29 | qRT-PCR | 60 | N/A | N/A | 69.76 (51–81) | I-IV | 7 | | Hu (2014) [34] | Taiwan | GC | PER3 | 29 | qRT-PCR | 60 | N/A | N/A | 69.76 (51–81) | I-IV | 7 | | Wang (2017) [36] | China | HNSCC | PER1 | 60 | IHC | 0-60 | (29/31) 48.33% | | 59 (41–84) | I-IV | 9 | | Wang (2017) [36] | China | HNSCC | PER2 | 60 | IHC | 0-60 | (27/33) 45% | | 59 (41–84) | I-IV | 9 | | Wang (2017) [36] | China | HNSCC | PER3 | 60 | IHC | 0-60 | (29/31) 48.33% | | 59 (41–84) | I-IV | 9 | | Hasakova (2018) [35] | Slovak Republic | CRC | PER2 | 38 | qRT-PCR | 0-60 | (19/19) 50% | Median value | | I-IV | 6 | | Hasakova (2018) [35] | Slovak Republic | CRC | PER2 | 23 | qRT-PCR | 0-60 | (11/12) 47.83% | Median value | | I-IV | 6 |
|
|
GC: gastric cancer; CRC: colorectal cancer; CC: colon cancer; PDA: pancreatic ductal adenocarcinoma; BC: breast cancer; GBM: glioblastoma; NSCLC: non-small cell lung cancer; OSCC: oral squamous cell carcinoma; HNSCC: head and neck squamous cell carcinoma; IHC: immunohistochemistry; qRT-PCR: real-time quantitative reverse transcriptase-polymerase chain reaction; SP: staining intensity score and percentage of positive cells; NA: not available.
|
